Pluristem Wants Bloomberg Retraction, Array Sets Secondary: Healthcare Biz Wrap

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Agenus (NASDAQ:AGEN) reports that efficacy is shown with GlaxoSmithKline’s (NYSE:GSK) Phase 3 malaria vaccine candidate, which contains AGEN’s Qs-21 Stimulon adjuvant. Infants in the trial who received the vaccine suffered one-third fewer episodes of both clinical and severe malaria.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Shares of Pluristem Therapeutics (NASDAQ:PSTI) popped following its response to a Bloomberg article which reported that the second of three patients given the company’s experimental stem cells died, subsequent to the firm touting the treatments as “life-saving.” Now, Pluristem wants Bloomberg to publish a correction, as it says the article is “factually inaccurate and misleading.”

Drug developer Array BioPharma (NASDAQ:ARRY) shares moved down sharply after the firm priced an 18 million share secondary offering at $3.65, which marks a 10 percent discount to Thursday’s close. The firm had 95.4 million shares outstanding as of October, which would make the divestiture almost a 19 percent dilution to its float.

Don’t Miss: AAII Sentiment Survey: Optimism Back to Summer Levels.

More Articles About:

To contact the reporter on this story: To contact the editor responsible for this story:

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business